摘要
【目的】探讨不同剂量替格瑞洛对急性心肌梗死(AMI)行经皮冠状动脉介入术(PCI)治疗后再缺血患者的临床疗效。【方法】选择2020年4月至2021年11月于延安大学咸阳医院行PCI的治疗的64例AMI患者,根据治疗方法不同将其分为观察组和对照组,每组32例。比较两组治疗前后血小板功能[血小板聚集率、血小板计数、酶体膜糖蛋白63(CD63)、α颗粒膜糖蛋白62p(CD62p)]、冠状动脉血流参数[收缩期血流峰值(SPV)、舒张期血流峰值(DPV)、冠脉血流储备(CFVR)]、心肌损伤指标[缺血修饰白蛋白(IMA)、心肌肌钙蛋白Ⅰ(cTnⅠ)、肌红蛋白(Mb)、肌酸激酶同工酶(CK-MB)]、炎症因子[超敏C反应蛋白(hs-CRP)、细胞间黏附分子-1(ICAM-1)、巨噬细胞衍生趋化因子(MDC)、白介素-10(IL-10)]及治疗后不良反应发生率。【结果】治疗后,两组患者血小板聚集率、血小板计数、CD63、CD62p均低于治疗前,且观察组低于对照组(P<0.05);两组患者DPV、SPV、CFVR均高于治疗前,且观察组高于对照组(P<0.05);两组患者IMA、cTnI、Mb、CK-MB水平均低于治疗前,且观察组低于对照组(P<0.05);两组hs-CRP、ICAM-1、MDC、IL-10水平低于治疗前,且观察组低于对照组(P<0.05)。观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。【结论】负荷剂量替格瑞洛治疗AMI患者,可改善PCI术后再缺血患者血小板功能、冠状动脉血流,减轻心肌损伤,降低炎症因子水平,对改善患者预后具有重要意义。
【Objective】To investigate the clinical efficacy of different doses of Tigrillo in patients with acute myocardial infarction(AMI)who underwent percutaneous coronary intervention(PCI)for reperfusion.【Methods】A total of 64 AMI patients who underwent PCI surgery Xianyang Hospital of Yan'an University from April 2020 to November 2021 were selected and divided into an observation group and a control group based on different treatment methods,with 32 patients in each group.Comparison of the two groups before and after treatment was conducted including platelet function[Platelet aggregation rate,platelet count,enzyme membrane glycoprotein 63(CD63)αGranular membrane glycoprotein 62p(CD62p)],coronary artery blood flow parameters[Peak systolic blood flow(SPV),peak diastolic blood flow(DPV),coronary flow reserve(CFVR)],myocardial injury indicators[Ischemic modified albumin(IMA),cardiac troponinⅠ(cTnⅠ),myoglobin(Mb),creatine kinase isoenzyme(CK-MB)],inflammatory factors[Hypersensitivity C-reactive protein(hs-CRP),intercellular adhesion molecule-1(ICAM-1),macrophage derived chemokine(MDC),interleukin-10(IL-10)],and the incidence of adverse reactions after treatment.【Results】After treatment,the platelet aggregation rate,platelet count,CD63,and CD62p in both groups of patients were lower than before treatment,and the observation group was lower than the control group(P<0.05);The DPV,SPV,and CFVR of both groups of patients were higher than before treatment,and the observation group was higher than the control group(P<0.05);The levels of IMA,cTnI,Mb,and CK-MB in both groups of patients were lower than before treatment,and the observation group was lower than the control group(P<0.05);The levels of hs-CRP,ICAM-1,MDC,and IL-10 in both groups were lower than before treatment,and the observation group was lower than the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).【Conclusion】The treatment o
作者
张会琴
王智刚
王小妮
ZHANG Hui-qin;WANG Zhi-gang;WANG Xiao-ni(Department of Cardiovascular Medicine,Xianyang Hospital of Yan'an University,Xianyang Shaanxi 712000)
出处
《医学临床研究》
CAS
2023年第8期1214-1217,共4页
Journal of Clinical Research
